CAMP-B评分预测慢性乙型肝炎患者HBsAg清除后肝细胞癌风险
该研究回顾性分析慢性乙型肝炎伴HBsAg清除患者,构建CAMP-B评分(肝硬化、年龄≥50岁、男性、血小板<150,000/mm3),训练队列3476例来自韩国两家医院,外部验证5255例来自香港。HCC年发生率训练队列0.43%、验证队列0.24%,评分可分层HCC风险。
要点
- CAMP-B评分由肝硬化、年龄≥50岁、男性、血小板<150,000/mm3构成,均独立关联HCC风险。
- 训练队列HCC年发生率0.43%,验证队列0.24%。
- 验证队列低、中、高风险组HCC发生率分别为0.07%、0.37%、0.90%。
核心结论
- CAMP-B评分与HBsAg清除后HCC发生显著相关,可易于在真实临床实践中实施并帮助分层HCC风险。
研究设计与样本
- 回顾性分析慢性乙型肝炎伴HBsAg清除患者,训练队列为韩国两家医院3476例,外部验证为香港5255例。
主要发现
- 训练队列24,019人年观察期间102例发生HCC(0.43%/年)。
- 验证队列85例发生HCC(0.24%/年)。
- 训练队列5、10、15年时间依赖ROC曲线下面积分别为0.782、0.817、0.825;验证队列分别为0.785、0.771、0.796。
- 验证队列低、中、高风险组HCC发生率分别为0.07%、0.37%、0.90%。
关键数值与推荐
- 风险评分:肝硬化(C)3分,年龄≥50岁(A)2分,男性(M)3分,血小板计数<150,000/mm3(P)1分。
临床怎么用
- CAMP-B评分可易于在真实临床实践中实施,并帮助分层HBsAg清除后慢性乙型肝炎患者的HCC风险。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Risk of hepatocellular carcinoma (HCC) persists after hepatitis B surface antigen (HBsAg) seroclearance in patients with chronic hepatitis B (CHB). AIMS: To identify risk factors and construct a predictive model for HCC development. METHODS: We retrospectively analysed patients with CHB with HBsAg seroclearance. Primary outcome was HCC development. Factors identified from a multivariate Cox model in the training cohort, consisting of 3476 patients from two Korean hospitals, were used to construct the prediction model. External validation was performed using data from 5255 patients in Hong Kong. RESULTS: In the training cohort, HCC occurred in 102 patients during 24,019 person-years of observation (0.43%/year). Risk scores were assigned to cirrhosis (C:3), age ≥50 years (A:2), male sex (M:3) and platelet count <150,000/mm3 (P:1); all were independently associated with an increased risk of HCC in multivariate analysis The time-dependent area under receiver operating characteristic curves for 5, 10 and 15 years in the training and validation cohorts were 0.782, 0.817 and 0.825 and 0.785, 0.771 and 0.796, respectively. In the validation cohort, 85 patients developed HCC (0.24%/year). The corresponding incidence of HCC in the low-, intermediate- and high-risk groups were 0.07%, 0.37% and 0.90%, respectively. CONCLUSIONS: The CAMP-B score (cirrhosis, age ≥50 years, male sex and platelet count <150,000/mm3/L) was significantly associated with HCC development after HBsAg seroclearance. CAMP-B score can be easily implemented in real-world clinical practice and helps stratify HCC risk in patients with CHB following HBsAg seroclearance.
引用
- Lee HW, Yip TC, Wong VW, et al. CAMP-B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance. Aliment Pharmacol Ther. 2024. PMID: 38425096. doi:10.1111/apt.17933
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。